ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0349

Disease Activity of Juvenil Idiopathic Arthritis in Transitional Care

Karen Carpio Astudillo1, Daniel clemente Garulo2, Juan Carlos Lopez-Robledillo3, Camille Bourgeois Avella4, Laura Trives Folguera4, Amparo López López1, Jose María Alvaro-Gracias4, Indalecio Monteagudo Sáez1 and Juan carlos Nieto-Gonzalez5, 1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Pediatric Rheumatology Unit, Hospital Niño Jesús, Madrid, Spain, 3Hospital Infantil Universitario Niño Jesús, Madrid, Spain, 4Hospital General Universitario Gregorio Marañon, Madrid, Spain, 5Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Meeting: ACR Convergence 2023

Keywords: Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile Idiopathic Arthritis (JIA) are a group of heterogeneous arthritis with onset in childhood. According to previous studies, this patients experience an improvement of their disease activity, functionality and even remission as they become young adults 1. Transitional care units aim to coordinate an uninterrupted follow-up in patients with chronic diseases.2 Our transitional care unit attend patients from 18 to 25 years old who have been previously diagnosed with any rheumatic disease during childhood. Our primary objective was to describe the disease activity of JIA patients at the transference to our unit and the remission maintenance during follow-up.

Methods: We conducted an observational retrospective longitudinal study from a cohort of patients with JIA who have been transferred to our transitional care unit. We selected patients with at least one clinical visit and have active follow-up. We collected demographic data, JIA classification, previous treatments and the treatment at time of transfer, articular and ocular flares, remission defined by Wallace criteria3 and changes in treatment during follow-up.

Results: From December 2016 to December 2021 we received 113 with JIA diagnosis, the mean age at transfer was 19.8 years. Demographic characteristics of patients are shown in Table 1. About 31% of the patients had a flare through the 3 years of follow-up, most of them were women (71.4%). Both oligoarticular (37.1%) and polyarticular (37.1%) and spondyloarthritis (25.7%) had inflamamatory flares in similar proportion.

It is important to notice that from 45 patients (38.9%) who had a flare prior to transfer 37.8% had another flare during follow-up. While, 26.5% of the patients who never had a previous flare presented a new flare during this follow-up. Flares during transfer were independent from patient’s previous inflammatory activity; and the previous treatment did not influence the risk of flare development.

Conclusion: Flare risk during transfer was independent from previous activity and treatment. The flare frequency was slightly reduced over time (39,8% vs. 31%) (Table 2).

Supporting image 1

Supporting image 2


Disclosures: K. Carpio Astudillo: None; D. clemente Garulo: Eli Lilly, 5, GlaxoSmithKlein(GSK), 6, Pfizer, 6, Sanofi, 5; J. Lopez-Robledillo: None; C. Bourgeois Avella: None; L. Trives Folguera: None; A. López López: None; J. Alvaro-Gracias: Abbvie, 2, 6, AstraZeneca, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Gilead, 2, 6, GSK, 2, 6, Merck/MSD, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB, 2, 6; I. Monteagudo Sáez: None; J. Nieto-Gonzalez: AbbVie, 2, 6, Amgen, 2, 6, Biogen, 6, Bristol-Myers Squibb(BMS), 6, FAES Farma, 6, Galapagos, 2, GSK, 2, Janssen, 2, 6, Lilly, 6, MSD, 2, 6, Novartis, 6, Pfizer, 6, Roche, 6, Sanofi, 6, UCB, 6.

To cite this abstract in AMA style:

Carpio Astudillo K, clemente Garulo D, Lopez-Robledillo J, Bourgeois Avella C, Trives Folguera L, López López A, Alvaro-Gracias J, Monteagudo Sáez I, Nieto-Gonzalez J. Disease Activity of Juvenil Idiopathic Arthritis in Transitional Care [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/disease-activity-of-juvenil-idiopathic-arthritis-in-transitional-care/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-of-juvenil-idiopathic-arthritis-in-transitional-care/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology